The total return over the past 12 months is +323.68% vs. +16.94% for the S&P 500. So far it's up +178.41% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +323.44% | +50.80% | +20.14% | (18.11%) | (27.25%) | (41.14%) |
| Total Return CAGR | +323.68% | +77.99% | +32.76% | (13.93%) | (24.80%) | (39.65%) |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Oruka Therapeutics, Inc. (ORKA)
| Year | Start price | End price | ORKA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $30.31 | $84.38 | +178.41% | +14.51% | +163.90% |
| 2025 | $19.39 | $30.31 | +56.35% | +17.72% | +38.63% |
| 2024 | $20.40 | $19.39 | +56.35% | +24.89% | +31.46% |
| 2023 | $28.44 | $20.40 | (28.21%) | +26.19% | (54.40%) |
| 2022 | $25.80 | $28.44 | +10.03% | (18.17%) | +28.20% |
| 2021 | $48.12 | $25.80 | (46.30%) | +28.74% | (75.04%) |
| 2020 | $68.52 | $48.12 | (29.79%) | +18.37% | (48.16%) |
| 2019 | $71.28 | $68.52 | (3.86%) | +31.22% | (35.08%) |
| 2018 | $291.60 | $71.28 | (75.56%) | (4.56%) | (71.00%) |
| 2017 | $615.60 | $291.60 | (52.64%) | +21.70% | (74.34%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
